Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America
View original at finance.yahoo.comNovo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Wegovy pill represents a significant innovation as the first and only GLP-1 pill for weight loss
80% confidenceMillions have been prescribed Wegovy (semaglutide) injection 2.4 mg for weight management since 2021
80% confidenceThere are people interested in addressing their weight who have been waiting for a medicine that was right for them, and for many that wait is over with Wegovy pill offering powerful efficacy in a once-daily pill
80% confidenceMore than 100 million Americans are living with obesity
80% confidenceObesity is not just a disease of lack of willpower but has underlying biology that may impede people from losing weight and keeping it off
80% confidenceWegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials
80% confidence
Data points we hold from this source
| Novo Nordisk A/S · us employee count | 10000 employees |